Loading...
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio, Andrea Gunsoy, Necdet B. Baio, Gianluca Martin, Alan Paly, Victoria F. Risebrough, Nancy Halpin, David M. G. Singh, Dave Wise, Robert A. Han, MeiLan K.
Gabrio, Andrea
Gunsoy, Necdet B.
Baio, Gianluca
Martin, Alan
Paly, Victoria F.
Risebrough, Nancy
Halpin, David M. G.
Singh, Dave
Wise, Robert A.
Han, MeiLan K.
Citations
Altmetric:
Genre
Journal article
Date
2022-07-25
Advisor
Committee member
Group
Department
Thoracic Medicine and Surgery
Medicine
Medicine
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.2147/copd.s342244
Abstract
Objectives: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to determine whether this translated into differences in COPD-related healthcare resource utilization (HRU) costs in a United Kingdom (UK) setting. Methods: In a within-trial analysis, individual patient data from the IMPACT intention-to-treat (ITT) population were analyzed to estimate rates of COPD-related HRU with FF/UMEC/VI, FF/VI, or UMEC/VI. A Bayesian approach was applied to address issues typically encountered with this kind of data, namely data missing due to early study withdrawal, subjects with zero reported HRU, and skewness. Rates of HRU were estimated under alternate assumptions of data being missing at random (MAR) or missing not at random (MNAR). UK-specific unit costs were then applied to estimated HRU rates to calculate treatment-specific costs. Results: Under each MNAR scenario, per patient per year (PPPY) rates of COPD-related HRU were lowest amongst those patients who received treatment with FF/UMEC/VI compared with those receiving either FF/VI or UMEC/VI. Although absolute HRU rates and costs were typically higher for all treatment groups under MNAR scenarios versus MAR, final economic conclusions were robust to patient withdrawals. Conclusions: PPPY rates were typically lower with FF/UMEC/VI versus FF/VI or UMEC/VI.
Description
Citation
Citation to related work
Taylor and Francis
Has part
International Journal of Chronic Obstructive Pulmonary Disease, Vol. 17
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu